Chief development leader at Processa (NASDAQ: PCSA) moves to part-time post
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Processa Pharmaceuticals is changing the role of Dr. Sian Bigora as she moves toward retirement. Effective May 1, 2026, she will shift from a full-time executive officer position to a part-time employee role but will retain her title of Chief Development and Regulatory Officer.
After this change, she will no longer be treated as an “executive officer” under Section 16 of the Exchange Act, yet she will continue providing services in a reduced capacity. Her current employment agreement will end and be replaced with a new part-time arrangement, while she keeps previously granted equity awards and remains eligible for any prior bonus awards under their original terms.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Terms
executive officer, Section 16 of the Securities Exchange Act of 1934, equity awards, emerging growth company
4 terms
executive officer financial
"she will no longer be designated as an “executive officer” for purposes of Section 16"
Section 16 of the Securities Exchange Act of 1934 regulatory
"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
equity awards financial
"Dr. Bigora will continue to be entitled to any equity awards previously granted to her"
Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Processa Pharmaceuticals (PCSA) announce about Dr. Sian Bigora?
Processa Pharmaceuticals announced a planned transition for Dr. Sian Bigora as she moves toward retirement. Effective May 1, 2026, she will move from a full-time executive officer role to a part-time employee position while keeping her Chief Development and Regulatory Officer title.
Will Dr. Sian Bigora remain an executive officer at Processa Pharmaceuticals (PCSA)?
No. Effective May 1, 2026, Dr. Sian Bigora will no longer be designated an “executive officer” for Section 16 of the Exchange Act. She will continue working for Processa as a part-time employee but outside the executive officer group defined for reporting purposes.
How does the employment agreement of Dr. Sian Bigora change at Processa (PCSA)?
Dr. Sian Bigora’s existing full-time employment agreement will terminate on May 1, 2026. It will be replaced by a new part-time employment arrangement that reflects her reduced schedule while she continues serving as Chief Development and Regulatory Officer for Processa Pharmaceuticals.
What happens to Dr. Sian Bigora’s equity awards at Processa Pharmaceuticals (PCSA)?
Dr. Sian Bigora will keep all equity awards previously granted to her, subject to the existing plan and award terms. The transition to part-time status does not cancel these awards, and she remains eligible to receive any previously awarded bonus compensation under its original conditions.
Does Dr. Sian Bigora’s transition at Processa (PCSA) affect her bonus eligibility?
The company states that Dr. Sian Bigora will still be eligible to receive any previously awarded bonus compensation. These bonuses will be paid, if earned, in accordance with their original terms, despite her move from full-time executive officer to part-time employee status.